Updated on 10 August 2026
Improve the Quality of Life of Older Cancer Patients
Research Coordinator at KIST Europe
Saarbrücken, Germany
About
Who we are — Korea University Anam Hospital (Family Medicine) & KIST
Two complementary Korean entities seeking to join a forming EU consortium under HORIZON-MISS-2026-02-CANCER-07 — Improve the Quality of Life of Older Cancer Patients. South Korea is a Horizon Europe Pillar II Associated Country, and both entities are eligible for direct EU funding and named work-package roles on equal terms with EU partners.
Why our contribution is distinctive
-
Muscle-health focus for older cancer patients: sarcopenia, cachexia and frailty as key drivers of toxicity, loss of independence and poor QoL
-
Clinical + technology integration: geriatric oncology care and prehabilitation combined with wearables, biosensors, AI risk prediction and multi-omics
-
Translation-ready contribution: prospective cohort access, longitudinal follow-up, multimodal sensing and real-world data integration
Korea University Anam Hospital — Department of Family Medicine
Clinical & care-model strengths
-
Geriatric & frailty assessment: validated CGA, SPPB, grip-strength and gait-speed protocols
-
Sarcopenia & cachexia evaluation: CT/DEXA body-composition analysis, nutritional assessment and clinical biomarker work-up
-
Prehabilitation & rehabilitation: structured exercise, nutritional and psychosocial programmes before and during cancer treatment
-
Primary-care integration: bridging specialist oncology and community-level care to sustain QoL and independence
-
Clinical cohort access: established older-patient population across diverse cancer types; capacity for prospective enrolment and longitudinal follow-up
KIST — Center for Advanced Biomolecular Recognition
Technology & data strengths
-
AI-integrated sensing & risk prediction: ML models for frailty progression and QoL-decline prediction using multimodal sensor data
-
EG-FET biomarker platforms: minimally invasive, real-time detection of myokines, cachexia markers and inflammatory signatures
-
Wearables & continuous monitoring: sensor-fusion systems for longitudinal health-status tracking in free-living conditions
-
Myokine & cachexia multi-omics: molecular characterization of muscle–organ crosstalk relevant to sarcopenia, cancer cachexia and treatment toxicity
What we can contribute as partners
-
Clinical validation and intervention delivery for older cancer patients
-
Muscle-health biomarker and sensing development
-
Wearable-based longitudinal monitoring
-
AI-supported risk modelling for frailty progression and QoL decline
-
Multimodal data integration across clinical, sensor and molecular layers
-
Named WP roles, including work-package co-leadership where relevant
The consortium we hope to join
We are looking for a forming consortium that brings complementary strengths — in particular:
-
Geriatric oncology clinical sites across multiple EU Member States
-
Patient / survivor / caregiver involvement
-
SSH (social sciences, psychology, behavioural and caregiver research)
-
HTA / health economics / implementation science
-
Rehabilitation / prehabilitation
-
EHDS / FAIR data / UNCAN.eu-aligned infrastructure
We would be happy to contribute as funded consortium partners and to take on clearly defined work-package roles within the consortium's structure.
Contact
Dr. Juyong Yoon | KIST Europe | juyong.yoon@kist-europe.de
Topic
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
Organisation
Similar opportunities
Project cooperation
Multi-scale Cancer Digital Twin
- HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
Juyong Yoon
Research Coordinator at KIST Europe
Saarbrücken, Germany
Project cooperation
Arshia Gratiot
Founder at Eupnoos
London, United Kingdom
Project cooperation
- Offering Expertise to Consortias
- Design - setting the project scope
- HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
- HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
Tânia Cruz
Grant Writer and Advisor at Research Centre of the Portuguese Oncology Institute of Lisbon Francisco Gentil
Lisbon, Portugal